Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPER: Pembrolizumab + Platinum + Gemcitabine in R/M HNSCC
NCT05286619Phase 2Recruiting
- Sponsor
- Universiti Malaya
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Universiti Malaya. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05286619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286619.